PDT For Induction Therapy For Head And Neck Cancer

This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

Trial Details

NCT ID

NCT07214987

Phase

PHASE2

Sponsor

Massachusetts General Hospital

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Toripalimab-tpzi
Cisplatin
Docetaxel

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Participants must have a new diagnosis of histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, h…
Participants with HPV-independent SCC or HNSCC or other head and neck subsites must have stage III or non-metastatic stage IV at the time of diagno…
Participants must be determined by the investigator to be candidates for induction systemic therapy due to reasons such as the extent of primary tu…
Age ≥18 years. Because no dosing or adverse event data are currently available on the use of toripalimab in combination with cisplatin and docetaxe…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →